FORM 6-K<\/p>\n
\u00a0<\/p>\n
\nSECURITIES
\nAND EXCHANGE COMMISSION<\/p>\n
\nWashington,
\nD.C. 20549<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
\nReport
\nof Foreign Issuer<\/p>\n
\u00a0<\/p>\n
\nPursuant
\nto Rule 13a-16 or 15d-16 of<\/p>\n
\nthe
\nSecurities Exchange Act of 1934<\/p>\n
\n\u00a0<\/p>\n
\nFor the
\nmonth of June 2026\u00a0<\/p>\n
\n\u00a0<\/p>\n
\nCommission
\nFile Number: 001-11960<\/p>\n
\n\u00a0<\/p>\n
AstraZeneca PLC<\/p>\n
\n\u00a0<\/p>\n
\n1
\nFrancis Crick Avenue<\/p>\n
\nCambridge
\nBiomedical Campus<\/p>\n
\nCambridge
\nCB2 0AA<\/p>\n
\nUnited
\nKingdom<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
\nIndicate
\nby check mark whether the registrant files or will file annual
\nreports under cover of Form 20-F or Form 40-F.<\/p>\n
\u00a0<\/p>\n
\nForm
\n20-F X Form 40-F __<\/p>\n
\u00a0<\/p>\n
\nIndicate
\nby check mark if the registrant is submitting the Form 6-K in paper
\nas permitted by Regulation S-T Rule 101(b)(1):<\/p>\n
\u00a0<\/p>\n
\nIndicate
\nby check mark if the registrant is submitting the Form 6-K in paper
\nas permitted by Regulation S-T Rule 101(b)(7): ______<\/p>\n
\u00a0<\/p>\n
\nIndicate
\nby check mark whether the registrant by furnishing the information
\ncontained in this Form is also thereby furnishing the information
\nto the Commission pursuant to Rule 12g3-2(b) under the Securities
\nExchange Act of 1934.<\/p>\n
\u00a0<\/p>\n
\nYes __
\nNo X<\/p>\n
\u00a0<\/p>\n
\nIf
\n\u201cYes\u201d is marked, indicate below the file number
\nassigned to the Registrant in connection with Rule 12g3-2(b):
\n82-_____________<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
AstraZeneca PLC<\/p>\n
\n\u00a0<\/p>\n
\nINDEX
\nTO EXHIBITS<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
1.<\/p>\n
\nEnhertu approved in EU for HER2+ solid tumours<\/p>\n
\n\u00a0<\/p>\n
\u00a029 June 2026<\/p>\n
\u00a0<\/p>\n
Enhertu\u00a0approved
\nin the EU as first tumour agnostic HER2-directed therapy and
\nantibody drug conjugate for patients with previously treated
\nHER2-positive metastatic solid tumours<\/p>\n
\u00a0<\/p>\n
Based on three Phase II trials of AstraZeneca and Daiichi Sankyo’s
\nEnhertu which demonstrated clinically meaningful responses across a
\nbroad range of tumours<\/p>\n
\u00a0<\/p>\n
AstraZeneca and Daiichi Sankyo’s\u00a0Enhertu\u00a0(trastuzumab deruxtecan) has been approved
\nin the European Union (EU) as a monotherapy for the treatment of
\nadult patients with unresectable or metastatic HER2-positive
\n(immunohistochemistry [IHC] 3+) solid tumours who have received
\nprior treatment and who have no satisfactory treatment
\noptions.<\/p>\n
\u00a0<\/p>\n
The approval by the European Commission follows the positive
\nopinion of the Committee for Medicinal Products for Human Use
\n(CHMP) of the European Medicines Agency (EMA) and is based on
\nresults from a subgroup of patients with HER2-positive (IHC 3+)
\ntumours across three\u00a0Phase II trials,\u00a0DESTINY-PanTumor02,\u00a0DESTINY-Lung01\u00a0and\u00a0DESTINY-CRC02.<\/p>\n
\n\u00a0<\/p>\n
Benedikt Westphalen, MD, Head of the Precision Oncology Program,
\nComprehensive Cancer Center of the University of Munich, Germany,
\nsaid: “HER2 overexpression occurs across multiple tumour types and
\nis associated with aggressive disease and a poor prognosis. Until
\nnow, HER2-directed therapies were only available for specific
\ntumour types. The approval of trastuzumab deruxtecan as a
\ntumour-agnostic therapy opens a new treatment option for patients
\nwith HER2-positive cancers regardless of where the tumour
\noriginated.”<\/p>\n
\u00a0<\/p>\n
Dave Fredrickson, Executive Vice President, Oncology Haematology
\nBusiness Unit, AstraZeneca, said: “Precision medicine is reshaping
\ncancer care by helping inform treatment decisions based on the
\nmolecular and biological characteristics of a patient’s
\ndisease.\u00a0Enhertu\u00a0is already approved in\u00a0breast, gastric,
\nand lung cancers, and with this approval, clinicians may now
\nconsider\u00a0Enhertu\u00a0for
\npatients with\u00a0HER2-positive\u00a0status across multiple
\nadditional tumour types. This highlights the importance
\nof\u00a0biomarker testing\u00a0to identify eligible patients and
\nensure that those with\u00a0HER2-positive disease\u00a0are
\nconsidered for targeted treatment.”<\/p>\n
\u00a0<\/p>\n
Ken Keller, Global Head of Oncology Business, and President and
\nCEO, Daiichi Sankyo, Inc., said: “This approval
\nof\u00a0Enhertu\u00a0marks a significant milestone in the EU for
\npatients with HER2-positive metastatic solid tumours and
\nestablishes the first tumour-agnostic indication for a
\nHER2-directed therapy and antibody drug conjugate in the
\nregion.\u00a0Enhertu\u00a0is now approved for six indications in the
\nEU, which demonstrates our commitment to advancing innovative
\nmedicines in areas of high unmet need to patients with cancer.”
\n\u00a0<\/p>\n
\u00a0<\/p>\n
In the DESTINY-PanTumor02 Phase II trial,\u00a0Enhertu\u00a0demonstrated a confirmed objective response
\nrate (ORR) of 52.3%\u00a0(95% confidence interval [CI]
\n42.6-61.8)\u00a0and median duration of response (DOR) of 21.1
\nmonths\u00a0(95% CI 10.6-25.0)\u00a0in patients with previously
\ntreated centrally or locally assessed IHC 3+ solid tumours (n=111)
\nincluding biliary tract, bladder, cervical, endometrial,
\novarian,\u00a0pancreatic\u00a0or other tumours. In
\nDESTINY-Lung01,\u00a0Enhertu\u00a0demonstrated a confirmed ORR of
\n52.9%\u00a0(95% CI 27.8-77.0)\u00a0and median DOR of 6.9
\nmonths\u00a0(95% CI 4.0-9.8)\u00a0in patients with previously
\ntreated centrally confirmed IHC 3+ non-small cell lung cancer
\n(NSCLC) (n=17). In DESTINY-CRC02,\u00a0Enhertu\u00a0demonstrated a confirmed ORR of
\n46.9%\u00a0(95% CI 34.3-59.8)\u00a0and median DOR of 5.5
\nmonths\u00a0(95% CI 4.2-8.1)\u00a0in patients with previously
\ntreated centrally confirmed IHC 3+ colorectal cancer
\n(n=64).<\/p>\n
\u00a0<\/p>\n
The safety profile of\u00a0Enhertu\u00a0was based on a pooled analysis of patients
\nwith unresectable or metastatic HER2-positive (IHC 3+) solid
\ntumours enrolled in DESTINY-PanTumor02, DESTINY-Lung01,
\nDESTINY-CRC02 and DESTINY-Breast01, and was consistent with
\nprevious clinical trials, with no new safety concerns
\nidentified.<\/p>\n
\u00a0<\/p>\n
Enhertu\u00a0has received a
\ntumour agnostic indication in the US and other countries based on
\nthe DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02
\ntrials.<\/p>\n
\u00a0<\/p>\n
Additional regulatory submissions for\u00a0Enhertu\u00a0are under review in the EU, including in
\ncombination with pertuzumab for the 1st-line treatment of patients
\nwith unresectable or metastatic HER2-positive (IHC 3+ or ISH+)
\nbreast cancer based on data from the\u00a0DESTINY-Breast09\u00a0Phase
\nIII trial and for patients with HER2-positive (IHC 3+ or ISH+)
\nbreast cancer who have residual invasive disease after neoadjuvant
\nHER2-targeted treatment based on data from
\nthe\u00a0DESTINY-Breast05\u00a0Phase
\nIII trial.<\/p>\n
\u00a0<\/p>\n
\u200bEnhertu\u202fis a
\nspecifically engineered\u00a0HER2-directed\u202fDXd\u202fantibody
\ndrug conjugate (ADC) discovered by Daiichi Sankyo and being jointly
\ndeveloped and commercialised by AstraZeneca and Daiichi
\nSankyo.\u202f<\/p>\n
\u00a0<\/p>\n
Financial considerations<\/p>\n
Following this approval\u00a0in the EU, an amount of $25 million is due from
\nAstraZeneca to Daiichi Sankyo as a milestone payment for the
\ntumour-agnostic indication. Sales of\u00a0Enhertu\u00a0in most EU territories are recognised by
\nDaiichi Sankyo. For further details on the financial arrangements,
\nplease consult the collaboration agreement
\nfrom\u00a0March
\n2019.<\/p>\n
\u00a0<\/p>\n
Notes<\/p>\n
\u00a0<\/p>\n
HER2 expression in solid tumours<\/p>\n
HER2 is a tyrosine kinase receptor growth-promoting protein
\nexpressed on the surface of various tissue cells throughout the
\nbody and is involved in normal cell growth.1\u00a0HER2
\nprotein overexpression may occur as a result
\nof\u00a0HER2\u00a0gene amplification and is often associated
\nwith aggressive disease and poor prognosis in some
\ncancers.2\u00a0HER2
\noverexpression occurs in a range of solid tumours with the
\nprevalence varying by tumour type.3<\/p>\n
\u00a0<\/p>\n
HER2-directed therapies have been used to treat HER2 overexpression
\nin breast, gastric and biliary tract cancers in the
\nEU.1,4-6\u00a0Although
\nHER2 is overexpressed in additional solid tumour types including
\nlung, bladder, cervical, colorectal, endometrial, ovarian, salivary
\ngland and pancreatic cancers, HER2 testing is not routinely
\nperformed for these additional tumour types and prior to this
\napproval there were no HER2-directed treatments approved in the EU
\nto treat a broad range of solid tumours.2,3,7,<\/p>\n
\u00a0<\/p>\n
DESTINY-PanTumor02<\/p>\n
DESTINY-PanTumor02 is a global, multicentre, multi-cohort,
\nopen-label, Phase II trial evaluating the efficacy and safety
\nof\u00a0Enhertu\u00a0(5.4mg\/kg) for the treatment of previously
\ntreated HER2-expressing tumours, including biliary tract, bladder,
\ncervical, endometrial, ovarian, pancreatic cancer or other
\ntumours.\u00a0<\/p>\n
\u00a0<\/p>\n
The primary endpoint of DESTINY-PanTumor02 is confirmed ORR as
\nassessed by investigator. Secondary endpoints include DOR, disease
\ncontrol rate (DCR), progression-free survival (PFS), overall
\nsurvival (OS), safety, tolerability and pharmacokinetics. Results
\nfrom DESTINY-PanTumor02 were published in
\nthe\u00a0Journal
\nof Clinical Oncology.8<\/p>\n
\u00a0<\/p>\n
DESTINY-PanTumor02 enrolled 267 HER2-positive (IHC 3+ [n=111] and
\nIHC 2+ [n=156]) adult patients at multiple sites in Asia, Europe,
\nNorth America, South America and Oceania. For more information
\nabout the trial, visit\u00a0ClinicalTrials.gov.<\/p>\n
\u00a0<\/p>\n
DESTINY-Lung01<\/p>\n
DESTINY-Lung01 is a global, open-label, two-cohort, Phase II trial
\nevaluating the efficacy and safety of\u00a0Enhertu\u00a0(5.4mg\/kg or 6.4mg\/kg) in patients
\nwith\u00a0HER2-mutant or HER2-overexpressing unresectable or
\nmetastatic NSCLC who had progressed after one or more systemic
\ntherapies.\u00a0<\/p>\n
\u00a0<\/p>\n
The primary endpoint of DESTINY-Lung01 is confirmed ORR by
\nindependent central review. Key secondary endpoints include DOR,
\nDCR, PFS, OS and safety. Results from the\u00a0HER2-mutant cohort were published
\nin\u00a0The
\nNew England Journal of Medicine\u00a0and results from the HER2-overexpressing
\ncohort were published in\u00a0The
\nLancet Oncology.9,10<\/p>\n
\u00a0<\/p>\n
DESTINY-Lung01 enrolled 181 adult patients (HER2-mutant [n=91] and
\nHER2-overexpressing [n=90; IHC 3+, n=17 and IHC 2+, n=73]) at
\nmultiple sites in Asia, Europe and North America. For more
\ninformation about the trial, visit\u00a0ClinicalTrials.gov.<\/p>\n
\u00a0<\/p>\n
DESTINY-CRC02<\/p>\n
DESTINY-CRC02 is a global, randomised, two-arm, parallel,
\nmulticentre, Phase II trial evaluating the efficacy and safety of
\ntwo doses (5.4mg\/kg or 6.4mg\/kg) of\u00a0Enhertu\u00a0in patients with locally advanced,
\nunresectable or metastatic HER2-positive (IHC 3+ or IHC 2+)
\ncolorectal cancer of BRAF wild-type, RAS wild-type or RAS mutant
\ntumour types previously treated with standard therapy. The trial
\nwas conducted in two stages. In the first stage, patients (n=80)
\nwere randomised 1:1 to receive either 5.4mg\/kg or 6.4mg\/kg
\nof\u00a0Enhertu. In the second stage, additional patients (n=42)
\nwere enrolled in the 5.4mg\/kg arm.\u00a0<\/p>\n
\u00a0<\/p>\n
The primary endpoint in DESTINY-CRC02 is confirmed ORR as assessed
\nby blinded independent central review. Secondary endpoints include
\nDOR, DCR, investigator-assessed confirmed ORR, clinical benefit
\nratio, PFS, OS and safety. Results from DESTINY-CRC02 were
\npublished in\u00a0The
\nLancet Oncology.11<\/p>\n
\u00a0<\/p>\n
DESTINY-CRC02 enrolled 122 adult patients (including 64 patients
\nwith IHC 3+ receiving 5.4mg\/kg) at multiple sites in Asia, Europe,
\nNorth America and Oceania. For more information about the trial,
\nvisit\u00a0ClinicalTrials.gov.<\/p>\n
\u00a0<\/p>\n
Enhertu<\/p>\n
\u200bEnhertu\u202fis a
\nHER2-directed ADC. Designed using Daiichi Sankyo’s
\nproprietary\u00a0DXd\u00a0ADC Technology,\u202fEnhertu\u202fis
\nthe lead ADC in the oncology portfolio of Daiichi Sankyo and the
\nmost advanced programme in AstraZeneca’s ADC scientific
\nplatform.\u202fEnhertu\u202fconsists of a HER2 monoclonal antibody
\nattached to a number of\u00a0topoisomerase\u00a0I inhibitor
\npayloads (an\u00a0exatecan\u00a0derivative,\u00a0DXd) via
\ntetrapeptide-based cleavable linkers.\u00a0<\/p>\n
\u00a0<\/p>\n
Enhertu\u00a0(5.4mg\/kg) is
\napproved in the US as an adjuvant treatment for adult patients with
\nHER2-positive\u00a0(IHC 3+ or
\nISH+)\u00a0breast
\ncancer\u00a0who have residual invasive disease following
\ntrastuzumab (with or without pertuzumab) and taxane-based
\ntreatment\u00a0based on the\u00a0DESTINY-Breast05\u00a0trial.<\/p>\n
\u00a0<\/p>\n
Enhertu\u00a0(5.4mg\/kg)
\nfollowed by THP is approved in China and the US as a neoadjuvant
\ntreatment for adult patients with HER2-positive\u00a0(IHC 3+ or
\nISH+)\u00a0Stage II or Stage III breast cancer based on the results
\nfrom the\u00a0DESTINY-Breast11\u00a0trial.
\nContinued approval in China for this indication may be contingent
\nupon verification and description of clinical benefit in a
\nconfirmatory trial.\u00a0<\/p>\n
\u00a0<\/p>\n
Enhertu\u00a0(5.4mg\/kg)\u00a0in
\ncombination with pertuzumab is approved in the US, Switzerland,
\nUnited Arab Emirates, Saudi Arabia, Israel, Brazil and India as a
\n1st-line treatment for adult patients with unresectable or
\nmetastatic HER2-positive (IHC 3+ or ISH+) breast cancer, as
\ndetermined by an FDA-approved test,\u00a0based on the results from
\nthe\u00a0DESTINY-Breast09\u00a0trial.<\/p>\n
\u00a0<\/p>\n
Enhertu\u00a0(5.4mg\/kg) is
\napproved in more than 95 countries\/regions worldwide for the
\ntreatment of adult patients with unresectable or metastatic
\nHER2-positive (IHC 3+ or ISH+) breast cancer who have received a
\nprior anti-HER2-based regimen, either in the metastatic setting or
\nin the neoadjuvant or adjuvant setting, and have developed disease
\nrecurrence during or within six months of completing therapy based
\non the results from the\u00a0DESTINY-Breast03\u00a0trial.<\/p>\n
\u00a0<\/p>\n
Enhertu\u00a0(5.4mg\/kg) is
\napproved in more than 95 countries\/regions worldwide for the
\ntreatment of adult patients with unresectable or metastatic
\nHER2-low (IHC 1+ or IHC 2+\/ISH-) breast cancer who have received a
\nprior systemic therapy in the metastatic setting or developed
\ndisease recurrence during or within six months of completing
\nadjuvant chemotherapy based on the results from
\nthe\u00a0DESTINY-Breast04\u00a0trial.<\/p>\n
\u00a0<\/p>\n
Enhertu\u00a0(5.4mg\/kg) is
\napproved in more than 70 countries\/regions worldwide for the
\ntreatment of adult patients with unresectable or metastatic hormone
\nreceptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+\/ ISH-) or
\nHER2-ultralow (IHC 0 with membrane staining) breast cancer, as
\ndetermined by a locally or regionally approved test, that have
\nprogressed on one or more endocrine therapies in the metastatic
\nsetting based on the results from the\u00a0DESTINY-Breast06\u00a0trial.<\/p>\n
\u00a0<\/p>\n
Enhertu\u00a0(5.4mg\/kg) is
\napproved in more than 75 countries\/regions worldwide for the
\ntreatment of adult patients with unresectable or metastatic NSCLC
\nwhose tumours have activating\u00a0HER2\u00a0(ERBB2) mutations, as detected by a locally or
\nregionally approved test, and who have received a prior systemic
\ntherapy based on the results from the\u00a0DESTINY-Lung02\u00a0and\/or\u00a0DESTINY-Lung05\u00a0trials.
\nContinued approval in China and the US for this indication may be
\ncontingent upon verification and description of clinical benefit in
\na confirmatory trial.<\/p>\n
\u00a0<\/p>\n
Enhertu\u00a0(6.4mg\/kg) is
\napproved in more than 90 countries\/regions worldwide for the
\ntreatment of adult patients with locally advanced or metastatic
\nHER2-positive (IHC 3+ or IHC 2+\/ISH+) gastric or gastroesophageal
\njunction (GEJ) adenocarcinoma who have received a prior
\ntrastuzumab-based regimen based on the results from
\nthe\u00a0DESTINY-Gastric01,\u00a0DESTINY-Gastric02\u00a0and\/or\u00a0DESTINY-Gastric04\u00a0trials.<\/p>\n
\u00a0<\/p>\n
Enhertu\u00a0(5.4mg\/kg) is
\napproved in more than\u00a040\u00a0countries\/regions worldwide for
\nthe treatment of adult patients with unresectable or metastatic
\nHER2-positive (IHC 3+) solid tumours who have received prior
\nsystemic treatment and\/or have no satisfactory alternative
\ntreatment options based on efficacy results from
\nthe\u00a0DESTINY-PanTumor02,\u00a0DESTINY-Lung01,\u00a0DESTINY-CRC02\u00a0and\/or\u00a0HERALD\u00a0trials.\u00a0trials.
\nContinued approval\u00a0in the US\u00a0for
\nthis\u00a0indication\u00a0may be contingent upon verification and
\ndescription of clinical benefit in a confirmatory
\ntrial.<\/p>\n
\u00a0<\/p>\n
Enhertu\u00a0clinical development
\nprogramme\u00a0<\/p>\n
A comprehensive global clinical development programme is underway
\nevaluating the efficacy and safety of\u00a0Enhertu\u00a0as a monotherapy, in combination or
\nsequentially with other cancer medicines across multiple
\nHER2-targetable cancers.\u00a0\u00a0<\/p>\n
\u00a0<\/p>\n
\u200bDaiichi Sankyo collaboration\u00a0<\/p>\n
AstraZeneca and Daiichi Sankyo\u00a0entered into\u00a0a global
\ncollaboration to jointly develop and
\ncommercialise\u202fEnhertu\u202fin\u202fMarch
\n2019\u202fand\u202fDatroway\u202f(datopotamab\u00a0deruxtecan)
\nin\u202fJuly
\n2020, except
\nin Japan where Daiichi Sankyo\u00a0maintains\u00a0exclusive rights
\nfor each ADC. Daiichi Sankyo\u00a0is responsible for\u00a0the
\nmanufacturing and supply of\u202fEnhertu\u202fand\u202fDatroway.\u00a0<\/p>\n
\u00a0<\/p>\n
AstraZeneca in oncology\u00a0<\/p>\n
AstraZeneca is leading a revolution in oncology with the ambition
\nto provide cures for cancer in every form, following the science
\nto\u00a0understand\u00a0cancer and all its complexities to
\ndiscover, develop and deliver life-changing medicines to
\npatients.\u00a0<\/p>\n
\u00a0<\/p>\n
The Company’s focus is on some of the most challenging cancers. It
\nis through persistent innovation that AstraZeneca has built one of
\nthe most diverse portfolios and pipelines in the industry, with the
\npotential to catalyse changes in the practice of medicine and
\ntransform the patient experience.\u00a0<\/p>\n
\u00a0<\/p>\n
AstraZeneca has the vision to redefine cancer care and, one
\nday,\u00a0eliminate\u00a0cancer as a cause of
\ndeath.\u00a0<\/p>\n
\u00a0<\/p>\n
AstraZeneca<\/p>\n
AstraZeneca (LSE\/STO\/NYSE: AZN) is a global, science-led
\nbiopharmaceutical company that focuses on the discovery,
\ndevelopment, and commercialisation of prescription medicines in
\nOncology, Rare Disease, and BioPharmaceuticals, including
\nCardiovascular, Renal & Metabolism, and Respiratory &
\nImmunology. Based in Cambridge, UK, AstraZeneca’s innovative
\nmedicines are sold in more than 125 countries and used by millions
\nof patients worldwide. Please visit\u00a0astrazeneca.com\u00a0and
\nfollow the Company on Social Media\u00a0@AstraZeneca.<\/p>\n
\u00a0<\/p>\n
Contacts<\/p>\n
For details on how to contact the Investor Relations Team, please
\nclick\u00a0here.
\nFor Media contacts, click\u00a0here.<\/p>\n
\u00a0<\/p>\n
References<\/p>\n
\n1.\u00a0\u00a0\u00a0Iqbal N, Iqbal N. Human
\nEpidermal Growth Factor Receptor 2 (HER2) in Cancers:
\nOverexpression and Therapeutic
\nImplications.\u00a0Mol
\nBiol Int.
\n2014;2014:852748.<\/p>\n
\n2.\u00a0\u00a0 Cheng X. A comprehensive review of
\nHER2 in cancer biology and therapeutics.\u00a0Genes\u00a0(Basel).\u00a02024;15(7):903.<\/p>\n
\n3.\u00a0\u00a0\u00a0Ismail A, et al. HER2
\nalterations across solid tumour: implications for comprehensive
\ntesting.\u00a0Oncologist.\u00a02025;30(9):258.<\/p>\n
\n4.\u00a0\u00a0\u00a0Benli Y, et al.
\nHER2-targeted therapy in colorectal cancer: a comprehensive
\nreview.\u00a0Clin
\nTransl Oncol.
\n2025;27(9):3607-3624.<\/p>\n
\n5.\u00a0\u00a0\u00a0Uy NF, et al. HER2 in
\nnon-small cell lung cancer: a review of emerging
\ntherapies.\u00a0Cancers\u00a0(Basel).
\n2022;14(17):4155.<\/p>\n
\n6.\u00a0\u00a0\u00a0Haigh JE, et al. The
\nclinical utilisation and duration of treatment with HER2-directed
\ntherapies in HER2-positive recurrent or metastatic salivary gland
\ncancers.\u00a0Curr
\nOncol.\u00a02024;31(9):5652-5661.<\/p>\n
\n7.\u00a0\u00a0\u00a0Omar N, et al. HER2: An
\nemerging biomarker in non-breast and non-gastric
\ncancers.\u00a0Pathogenesis.
\n2015;2(3):1-9.<\/p>\n
\n8.\u00a0\u00a0\u00a0Meric-Bernstam F, et
\nal.\u00a0Efficacy and Safety of
\nTrastuzumab Deruxtecan in Patients With HER2-Expressing Solid
\nTumour: Primary Results From the DESTINY-PanTumor02 Phase II
\nTrial.\u00a0J
\nClin Oncol.
\n2023;42(1):47-58.<\/p>\n
\n9.\u00a0\u00a0 Li B, et al. Trastuzumab Deruxtecan
\nin HER2-Mutant Non-Small-Cell Lung Cancer.\u00a0N
\nEngl J Med.\u00a02022;386:241-251.<\/p>\n
\n10.\u00a0 Smit E, et al. Trastuzumab deruxtecan in
\npatients with metastatic non-small-cell lung cancer
\n(DESTINY-Lung01): primary results of the HER2-overexpressing
\ncohorts from a single-arm, phase 2 trial.\u00a0Lancet
\nOncol.
\n2024;25(4):439-454.<\/p>\n
\n11.\u00a0 Raghav K, et al. Trastuzumab deruxtecan
\nin patients with HER2-positive advanced colorectal cancer
\n(DESTINY-CRC02): primary results from a multicentre, randomised,
\nphase 2 trial.\u00a0Lancet
\nOncol.
\n2024;25(9):1147-1162.<\/p>\n
\u00a0<\/p>\n
Matthew Bowden<\/p>\n
Company Secretary<\/p>\n
AstraZeneca PLC<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
SIGNATURES<\/p>\n
\u00a0<\/p>\n
\nPursuant
\nto the requirements of the Securities Exchange Act of 1934, the
\nRegistrant has duly caused this report to be signed on its behalf
\nby the undersigned, thereunto duly authorized.<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
Date: 29 June 2026<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\nBy: \/s\/
\nMatthew Bowden<\/p>\n
\u00a0<\/p>\n
\nName:
\nMatthew Bowden<\/p>\n
\u00a0<\/p>\n
\nTitle:
\nCompany Secretary<\/p>\n
\n\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"FORM 6-K \u00a0 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 \u00a0 \u00a0 Report of Foreign Issuer \u00a0 Pursuant…\n","protected":false},"author":2,"featured_media":72847,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[24358,11153,21721,23044,33165,33198,12166,33199],"class_list":["post-72846","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-antibody-drug-conjugate","tag-astrazeneca","tag-azn","tag-daiichi-sankyo","tag-destiny-pantumor02","tag-enhertu-eu-approval","tag-oncology","tag-tumour-agnostic-her2-therapy"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116834858690574107","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/72846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=72846"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/72846\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/72847"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=72846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=72846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=72846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}